China · Delayed Price · Currency is CNY Bide Pharmatech Statistics
Total Valuation
Bide Pharmatech has a market cap or net worth of CNY 5.49 billion. The enterprise value is 4.60 billion.
| Market Cap | 5.49B |
| Enterprise Value | 4.60B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | Jun 10, 2026 |
Share Statistics
Bide Pharmatech has 86.15 million shares outstanding. The number of shares has decreased by -0.62% in one year.
| Current Share Class | 86.15M |
| Shares Outstanding | 86.15M |
| Shares Change (YoY) | -0.62% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 51.42% |
| Owned by Institutions (%) | 19.60% |
| Float | 33.07M |
Valuation Ratios
The trailing PE ratio is 30.66.
| PE Ratio | 30.66 |
| Forward PE | n/a |
| PS Ratio | 3.98 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | 67.32 |
| P/OCF Ratio | 52.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.18, with an EV/FCF ratio of 56.46.
| EV / Earnings | 25.34 |
| EV / Sales | 3.34 |
| EV / EBITDA | 17.18 |
| EV / EBIT | 18.91 |
| EV / FCF | 56.46 |
Financial Position
The company has a current ratio of 7.46, with a Debt / Equity ratio of 0.07.
| Current Ratio | 7.46 |
| Quick Ratio | 4.34 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | 1.68 |
| Interest Coverage | 41.96 |
Financial Efficiency
Return on equity (ROE) is 9.06% and return on invested capital (ROIC) is 16.37%.
| Return on Equity (ROE) | 9.06% |
| Return on Assets (ROA) | 6.06% |
| Return on Invested Capital (ROIC) | 16.37% |
| Return on Capital Employed (ROCE) | 11.16% |
| Weighted Average Cost of Capital (WACC) | 7.32% |
| Revenue Per Employee | 1.88M |
| Profits Per Employee | 247,463 |
| Employee Count | 734 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 0.85 |
Taxes
In the past 12 months, Bide Pharmatech has paid 49.90 million in taxes.
| Income Tax | 49.90M |
| Effective Tax Rate | 21.55% |
Stock Price Statistics
The stock price has decreased by -2.49% in the last 52 weeks. The beta is 0.58, so Bide Pharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -2.49% |
| 50-Day Moving Average | 59.29 |
| 200-Day Moving Average | 59.90 |
| Relative Strength Index (RSI) | 51.47 |
| Average Volume (20 Days) | 5,393,370 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bide Pharmatech had revenue of CNY 1.38 billion and earned 181.64 million in profits. Earnings per share was 2.08.
| Revenue | 1.38B |
| Gross Profit | 617.11M |
| Operating Income | 243.42M |
| Pretax Income | 231.54M |
| Net Income | 181.64M |
| EBITDA | 258.61M |
| EBIT | 243.42M |
| Earnings Per Share (EPS) | 2.08 |
Balance Sheet
The company has 1.02 billion in cash and 136.91 million in debt, with a net cash position of 885.69 million or 10.28 per share.
| Cash & Cash Equivalents | 1.02B |
| Total Debt | 136.91M |
| Net Cash | 885.69M |
| Net Cash Per Share | 10.28 |
| Equity (Book Value) | 2.06B |
| Book Value Per Share | 24.13 |
| Working Capital | 1.99B |
Cash Flow
In the last 12 months, operating cash flow was 103.84 million and capital expenditures -22.31 million, giving a free cash flow of 81.53 million.
| Operating Cash Flow | 103.84M |
| Capital Expenditures | -22.31M |
| Depreciation & Amortization | 15.19M |
| Net Borrowing | -130.76M |
| Free Cash Flow | 81.53M |
| FCF Per Share | 0.95 |
Margins
Gross margin is 44.75%, with operating and profit margins of 17.65% and 13.17%.
| Gross Margin | 44.75% |
| Operating Margin | 17.65% |
| Pretax Margin | 16.79% |
| Profit Margin | 13.17% |
| EBITDA Margin | 18.75% |
| EBIT Margin | 17.65% |
| FCF Margin | 5.91% |
Dividends & Yields
This stock pays an annual dividend of 1.16, which amounts to a dividend yield of 1.92%.
| Dividend Per Share | 1.16 |
| Dividend Yield | 1.92% |
| Dividend Growth (YoY) | 28.89% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 56.35% |
| Buyback Yield | 0.62% |
| Shareholder Yield | 2.54% |
| Earnings Yield | 3.31% |
| FCF Yield | 1.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 25, 2023. It was a forward split with a ratio of 1.4.
| Last Split Date | May 25, 2023 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |